HomeAI · summaries
Storia in 4 fonti
The future of gray-market peptides
FDA advisory panel voted to allow compounding pharmacies to make 6 of 7 peptides, despite safety/efficacy concerns, with Revelation Pharma's Shawn Hodges cautiously optimistic.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Pharmalittle: We're reading about a U.S. peptide panel's votes, Amgen scuffling with the FDA, and more
An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available
- ·
washingtonexaminer.com
Evidence vs influencers: The FDA vote putting patients in danger
Patient demand and influencer hype cannot replace clinical testing: the FDA must stop legitimizing unapproved compounded peptides.
